

Title	Metallothionein-3 is a clinical biomarker for tissue zinc levels in nasal mucosa
Author(s)	Suzuki, Masanobu; Ramezanpour, Mahnaz; Cooksley, Clare; Ogi, Kazuhiro; Psaltis, Alkis J.; Nakamaru, Yuji; Homma, Akihiro; Wormald, Peter-John; Vreugde, Sarah
Citation	Auris nasus larynx, 48(5), 890-897 https://doi.org/10.1016/j.anl.2021.01.019
Issue Date	2021-10
Doc URL	http://hdl.handle.net/2115/86879
Rights	© 2021. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Rights(URL)	http://creativecommons.org/licenses/by-nc-nd/4.0/
Туре	article (author version)
Additional Information	There are other files related to this item in HUSCAP. Check the above URL.
File Information	ANL 48(5) 890-897.pdf



1	Metallothionein-3 is a clinical biomarker for tissue zinc levels in nasal mucosa.
2	
3	Masanobu Suzuki ^{1,2} , Mahnaz Ramezanpour ¹ , Clare Cooksley ¹ , Kazuhiro Ogi ¹ , Alkis J
4	Psaltis ¹ , Yuji Nakamaru ² , Akihiro Homma ² , Peter-John Wormald ¹ , and Sarah
5	Vreugde ¹ .
6	
7	¹ Department of Surgery-Otorhinolaryngology Head and Neck Surgery, the Queen
8	Elizabeth Hospital, and the University of Adelaide, Adelaide, SA, 5061, Australia.
9	² Department of Otolaryngology-Head and Neck Surgery, Hokkaido University
10	Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido 060-8638,
11	Japan.
12	
13	Running title: MT3 is a biomarker for zinc in nasal mucosa.
14	
15	*Corresponding author:
16	Sarah Vreugde

- 17 Department of Surgery-Otolaryngology, Head and Neck Surgery. The University of
- 18 Adelaide, SA, Australia.
- 19 Phone: +618 8222 7158
- 20 Fax: +618 8222 7419
- 21 Email: sarah.vreugde@adelaide.edu.au
- 22
- 23 This study was supported by JSPS KAKENHI Grant Number 17H06491, 18K16871,
- 24 and 18KK0444, and GSK Japan Research Grant 2015, and the Akiyama life science
- 25 foundation to MS and Sanofi Japan research grant to AH.
- 26
- 27

2 Metallothionein-3 is a clinical biomarker for tissue zinc levels in nasal mucosa.

3

4 ABSTRUCT

5 **Objective:** Recently, depleted tissue zinc levels were found in nasal mucosa from patients with chronic rhinosinusitis (CRS) in correlation with tissue eosinophilia, 6 7 however, no clinical biomarkers for tissue zinc levels have been identified. 8 Metallothionein-3 (MT3) is an intracellular zinc chelator and previous data showed 9 MT3 mRNA levels to be reduced in CRS patients with nasal polyps (CRSwNP). In 10 this study, we examined the correlation between MT3 expression and zinc levels in 11 nasal mucosa and primary human nasal epithelial cells (HNECs) to investigate 12 whether MT3 could be a clinical biomarker for tissue zinc levels.

13 *Method*: Tissue was harvested from 36 patients and mounted on tissue micro-array

14 (TMA) slides. MT3 expression and tissue zinc fluorescence intensity were measured

15 at different areas within the mucosa (surface epithelium and lamina propria) and

16 compared between controls, CRSwNP and CRS without nasal polyps (CRSsNP)

17 patients. MT3 mRNA and protein expression were examined in zinc-depleted HNECs

18 by qPCR and immunofluorescence microscopy.

19 *Results:* MT3 expression in CRSwNP was significantly decreased in both surface

20 epithelium (p<0.001 to controls) and lamina propria (p=0.0491 to controls). There

21 was a significant positive correlation between tissue zinc levels and MT3 expression

22 in nasal mucosa (r=0.45, p=0.007). In zinc-deplete HNECs, MT3 expression was

significantly decreased at mRNA (p=0.02) and protein level (p<0.01). There was a

24 significant positive correlation between tissue zinc levels and MT3 expression within

25 individual HNECs (r= 0.59, p<0.001).

26 Conclusions: MT3 expression reflects intramucosal zinc levels in both nasal mucosa

- and HNECs indicating MT3 could be used as a clinical biomarker for monitoringintracellular zinc levels in the nasal mucosa.
- 29
- 30 Key words: chronic rhinosinusitis, human nasal epithelial cells, zinquin, and nasal
- 31 polyps
- 32

33 INTRODUCTION

Chronic rhinosinusitis (CRS) is defined as a sinonasal inflammation persisting for more than 12 weeks, characterized by infiltration of inflammatory cells into the nasal mucosa, tissue remodeling, and often accompanied by asthma(1, 2). CRS is clinically classified into two subtypes depending on the presence or absence of nasal polyps; CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP)(3).

40 Zinc is an essential trace element required for the normal functioning of many 41 organ systems including the immune system. Zinc deficiency decreases the function 42 of Th1 cells, but not that of Th2 cells and is associated with Th2 polarisation and 43 eosinophilic inflammation (4-6). Zinc depleted diet has been shown to promote 44 eosinophil infiltration into the lung in mice (7). Zinc depletion has been postulated to 45 be involved in the pathogenesis of bronchial asthma and atopic dermatitis(8-10). 46 Recently, depleted tissue zinc levels were reported in the nasal mucosa of 47 patients with CRS(11). Interestingly, whilst tissue zinc levels were decreased, there 48 was an increase in mucus zinc levels at sites of inflammation and no evidence of 49 systemic zinc depletion (11, 12). Mucosal zinc depletion is thought to be involved in 50 multiple aspects of the pathophysiology of CRS and is more severe in CRSwNP than 51 CRSsNP (11, 12). Reduced zinc levels impair epithelial barrier function at the level of 52 the nasal mucosa and promote pro-inflammatory cytokines expression(11). Mucosal 53 zinc levels are inversely correlated with eosinophil infiltration and affect tissue 54 remodeling, which concerns a cycle of deposition and removal of extracellular matrix 55 (ECM) proteins(12). Tissue eosinophil infiltration is seen in up to 70% of CRSwNP 56 patients and those patients often have extensive disease and poor prognosis compared 57 to non-eosinophilic CRS patients(13, 14).

58 Despite evidence of altered homeostasis of zinc in eosinophilic CRSwNP 59 patients and the role of zinc in the pathophysiology of CRS, there are no methods to 60 evaluate mucosal zinc levels in clinical practice. Serum zinc levels and zinc 61 transporter genes in nasal mucosa are not useful biomarkers, because there were no 62 significant differences in serum zinc levels and zinc transporter genes between 63 healthy controls and CRS patients(11, 12). 64 Metallothionein-3 (MT3) is a zinc chelator gene, the expression of which is 65 regulated by intracellular zinc levels. Our previous data showed MT3 mRNA was 66 significantly reduced in CRSwNP compared to controls (11). These findings indicate 67 that MT3 expression could be a new biomarker for mucosal zinc levels. However, 68 there are no reports on MT3 expression in nasal mucosa from CRS patients in relation 69 to mucosal zinc levels. It is also unknown whether MT3 expression reflects 70 intracellular zinc levels in primary human nasal epithelial cells (HNECs). 71 In this study, we examined the relationship between MT3 expression and tissue zinc 72 levels using a tissue micro array (TMA). We also investigated the effect of zinc 73 depletion on MT3 expression in HNECs using zinc-depleted medium. 74

76 MATERIALS AND METHODS

77 Patients and tissue collection

The study was approved by The Queen Elizabeth Hospital Human Research 78 79 Ethics Committee (reference HREC/15/TQEH/132). Written informed consent was 80 obtained from study participants prior to tissue or cell collection. Nasal mucosa was 81 taken from those patients undergoing endoscopic sinus surgery (ESS) for CRS or 82 skull base tumor resections. Donors were divided into control patients (patients with 83 skull base tumor), and CRSsNP or CRSwNP, depending on the absence or presence 84 of nasal polyps respectively, as defined by the European Position Paper(3). Ethmoidal 85 mucosa was used in control and CRSsNP patients and nasal polyps from middle 86 meatus were used for CRSwNP patients. Control patients were only included in the 87 absence of radiographic or endoscopic evidence of CRS. Patients with 88 immunosuppression and treatments with oral antibiotics or corticosteroids in the week 89 prior to study initiation were excluded. The sample pathologically diagnosed as 90 respiratory epithelial adenomatoid hamartoma (REAH) or nasal tumor were excluded. 91 92 Primary human nasal epithelial cell cultures 93 Primary human nasal epithelial cells (HNECs) were taken from the nasal 94 mucosa of donors in a method as previously described (15-17). The cells were

suspended in Bronchial Epithelial Growth Medium (BEGM, CC-3170, Lonza,

96 Walkersville, MD, USA), supplemented with 2% Ultroser G (Pall Corporation, Port

- 97 Washington, NY, USA). Monocytes were depleted from the cell suspension using
- 98 anti-CD68 antibody (Dako, Glostrup, Denmark) coated cell culture dishes. HNECs
- 99 were incubated in 37°C, humidified, 5% CO₂ in collagen-coated flasks (Thermo
- 100 Scientific, Walthman, MA, USA), until passage 2. The cells were confirmed of being

101	epithelial lineage by reactivity to PAN-cytokeratin and CD45 antibodies, and by
102	morphological examination with Diff-Quik analysis by qualified cytologists (IMVS
103	Cytology Department, The Queen Elizabeth Hospital, Adelaide, Australia).
104	
105	Zinc depleted media
106	5 grams of analytical grade Chelex 100 chelating ion-exchange resin (C7901,
107	Sigma, Saint Louis, MO, USA) in two separate 50 ml falcon tubes was washed twice
108	with Milli-Q water for 10 minutes. 50 ml of BEGM was added into the first tube and
109	incubated for 2 hours on a rotator at room temperature (RT), following transfer into
110	the other tube. After incubation overnight on a rotator at 4°C, the Chelex beads were
111	discarded and the media was collected. The depleted molecules except zinc were
112	added to the media (CaCl ₂ =22.19mg, Fe(NO ₃) ₃ =0.00014mg, FeSO ₄ =0.022mg,
113	MgSO ₄ =2.4mg, MgCl ₂ =4.28mg). The pH of the media was adjusted to original
114	BEGM.
115	
116	RNA extraction, Reverse transcription and qPCR.
117	HNECs were incubated in 6-well plates in normal and zinc deplete BEGM for
118	48 hours. Cells were collected and washed in phosphate buffered saline (PBS),
119	followed by RNA extraction using the RNeasy Mini Kit according to the
120	manufacturer's instructions (QIAGEN Pty Ltd., Australia). An on-column DNAse
121	treatment was performed with an RNase-Free DNase Set (QIAGEN Pty Ltd.,
122	Australia). Extracted RNA was quantified using the Nanodrop 1000
123	spectrophotometer (Thermo Fisher Scientific, Franklin, MA, USA). RNA was reverse
124	transcribed into cDNA using Quantitect Reverse Transcription kit (Qiagen, Hilden,
125	Germany) with a MyCycler Thermal Cycler (BioRad Laboratories Inc., Gladesville,

126	Australia). The resulting cDNA was subjected to qPCR with TAQman primer/probe
127	sets for each target gene, Taqman Universal Master Mix II (Thermo Fisher Scientific,
128	Scoresby, Australia) and nuclease-free water. The average threshold cycle (Ct) was
129	determined from three independent experiments and the level of gene expression
130	relative to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was determined
131	with the comparative CT method. Taqman Gene Assays used for gene expression
132	analysis were: Hs00359394_g1 (MT3) and Hs02758991 (GAPDH).
133	
134	Tissue Microarray
135	The analyses were conducted with the approval of the local Human Research

. .

136 Ethics Committee. Archival formalin-fixed paraffin-embedded sinus tissue blocks

137 collected from the patients who underwent sinonasal surgery were used to construct

138 the tissue microarray (TMA) for immunofluorescence. To guide the location of tissue

139 cores, a 4 µm section was sliced from each tissue block and stained using

140 Haematoxylin and Eosin (H&E). The tissue cores were punched using a 2 mm

141 disposable biopsy punch (Kai medical, Kai Europe GmbH, Solingen, Germany) and

142 manually put into Quick-RayTM paraffin recipient block 2 mm × 60 wells (IHC

143 World, Woodstock, MD, USA).

144

145 Immunofluorescence

Tissue samples were cut in 4 µm sections from the TMA block. The slice was
rehydrated, followed by antigen retrieval by submerging the slides in sodium citrate
buffer (10 mM sodium citrate buffer, pH 6.8) and incubating in a 1100W microwave
for 10 minutes. After cooling, sections were incubated with Serum Free Blocker (SFB,
Dako, Glostrup, Denmark) for 60 minutes at RT, followed by permeabilization with

151	1% SDS in PBS. The sections were blocked with SFB for 60 minutes at RT. Rabbit
152	polyclonal metallothionein 3 (MT3) antibody (A27974, Sigma-Aldrich, St Louis, MO,
153	USA), diluted to 4 μ g/mL in Tris-Buffered Saline-0.5% Tween (TBST), was added
154	and incubated overnight at 4 °C followed by washing with TBST to remove excess
155	primary antibody. 2 μ g/mL Cy3-conjugated donkey anti-rabbit antibody (Jackson
156	ImmunoResearch Labs Inc, West Grove, PA, USA) was then added and cells were
157	incubated for 1 hour at RT, followed by washing in TBST three times. 25 μ mol/L of
158	zinquin ethylester (Sigma-Aldrich, St. Louis, MO, USA) was added for 30 minutes at
159	37°C. The slides were washed, mounted with fluorescent mounting medium (Dako,
160	Glostrup, Denmark) and visualized by using a LSM700 Confocal Laser Scanning
161	Microscope (Zeiss Microscopy, Oberkochen, Germany) using the 20x objective.
162	Excitation and emission values for MT-3 and zinquin were 555/570 nm and 405/460
163	nm, respectively. All images were acquired with identical microscopy parameters and
164	taken sequentially to minimise cross-talk between fluorophores. Processing was
165	performed using ZEN Imaging Software (Carl Zeiss AG, Oberkochen, Germany).
166	The threshold of images was set for each channel to subtract autofluorescence and
167	background fluorescence due to unspecific binding of antibody. For each specimen, at
168	least 3 areas of the epithelium and the lamina propria were randomly selected as a
169	region of interest (ROI) as described(18-20), then quantification of zinquin intensity
170	was performed at the area. Quantification of MT-3 fluorescence intensity was
171	acquired within the same ROI where zinquin intensity was measured (Supplemental
172	Figure 1). Results are expressed as mean arbitrary fluorescence units, provided by the
173	ZEN imaging software.
174	Eastimetry of home and a filter a the calls were fixed with 2.5% formaling

174 For immunofluorescence of HNECs, the cells were fixed with 2.5% formalin175 in PBS for 10 minutes followed by washing with TBST four times. The cells were

176	permeabilized with 1% SDS in PBS and blocked with SFB. The following process
177	was identical as described above.

179 Statistical Analysis

180	All data was expressed as mean \pm Standard Deviation (SD). The intensity of
181	MT3 fluorescence was compared with Kruskal-Wallis test. When 3 or more groups
182	were compared, one-way Analysis Of Variance (ANOVA) followed by Tukey's test
183	was used to analyze differences among the groups. The Pearson correlation test was
184	used to determine the correlation among MT3 and zinquin intensity. P-values of
185	<0.05 were considered statistically significant. All the analyses were performed by
186	using the JMP® 11 (SAS Institute Inc., Cary, NC, USA).

188 RESULTS

190

189 MT3 expression is decreased in the mucosa of CRSwNP patients.

- First, we examined MT3 expression and zinquin fluorescence within the 191 mucosa using immunofluorescence assays on a TMA slide that included tissue cores
- 192 from 8 controls, 15 CRSsNP, and 13 CRSwNP. MT3 and zinquin fluorescence
- 193 intensity were measured at different areas within the mucosa (surface epithelium and
- 194 lamina propria) and compared amongst patient groups (Figure 1A). MT3 intensity in
- 195 CRSwNP tissue was significantly decreased in both surface epithelium (p=0.0006 to
- 196 controls, Figure 1B) and lamina propria (p=0.0491 to controls, Figure 1C). MT3
- 197 intensity in CRSsNP tissue was also significantly decreased in the surface epithelium
- 198 compared to controls (p=0.003, Figure 1B).
- 199

200 MT3 expression positively correlated with zinc levels in nasal mucosa.

201 Next, we determined the relation of labile zinc levels with the expression of 202 MT3 using immunofluorescence analysis of the TMA. There was a significant 203 positive correlation between MT3 and zinquin fluorescence intensity in nasal mucosa 204 (r=0.45, p=0.007, Figure 2).

205

206 MT3 expression correlates with zinc levels in nasal epithelial cells.

207 Next, we investigated the effect of zinc depletion of HNECs on MT3

208 expression. We established zinc deplete cells by culturing HNECs in zinc deplete

- 209 medium for 48 hours as previously reported(11, 12). Compared to control cells, in
- 210 zinc-deplete cells, MT3 fluorescence intensity was significantly decreased (control
- 211 57.83±10.83 vs zinc-deplete cells 36.68±4.51, p<0.01, Figure 3A and 3B). MT3
- 212 mRNA in zinc-depleted cells was also significantly decreased (0.45±0.26 fold change,

- 213 p=0.02, Figure 3C). There was a significant positive correlation between zinquin and
- 214 MT3 fluorescence intensity within individual cells (r=0.59, p<0.001) (Figure 3D).

216 DISCUSSION

217 This study showed that MT3 fluorescence intensity and mRNA expression 218 were significantly decreased in zinc-depleted HNECs in relation to zinc levels. In 219 addition, MT3 expression and labile zinc levels were significantly decreased in the 220 mucosa of CRSwNP patients, corresponding to previous reports showing zinc 221 depletion with decreased MT3 mRNA expression in CRSwNP(11). These results 222 suggest that MT3 mRNA and protein expression could be a new biomarker for tissue 223 zinc levels in nasal mucosa. 224 Zinc is an essential micronutrient and has a critical role in physiologic, 225 enzymatic and structural functions(21). Consequently, altered zinc homeostasis 226 affects multiple organs and systems and causes impaired immune function. In fact, 227 zinc depletion has been reported in many diseases, including rheumatoid arthritis(22), 228 hypertension(23), neurodegenerative diseases(24), Inflammatory Bowel Disease 229 (IBD)(25), type 2 diabetes mellitus(26, 27), atopic dermatitis(8), bronchial asthma(28, 230 29), and chronic rhinosinusitis (CRS)(10-12, 30). 231 Recently, altered zinc homeostasis has been thought to be involved in multiple 232 aspects of the pathophysiology of CRS, especially in CRSwNP patients(10). This 233 includes impaired epithelial barrier function, eosinophil infiltration and tissue 234 remodeling(11, 12). CRSwNP patients have been shown to present with lower 235 mucosal zinc levels in association with a reduced expression of the tight junction 236 protein Zonula Occludens-1 (ZO-1) compared to controls(11). This finding is 237 supported by *in-vitro* results showing that zinc-depleted HNECs formed leaky 238 mucosal barriers (11).

Depleted zinc levels also affect immune responses in the nasal mucosa and
have been shown to promote pro-inflammatory cytokine production in HNECs(12).

241 Also, significant negative correlations between tissue zinc levels and eosinophil 242 infiltration into the nasal mucosa of CRS patients have been demonstrated, in line 243 with previous findings of Th2 polarisation and eosinophilia in the context of zinc 244 deficiency(4-6). Tissue zinc levels are also correlated with collagen abundance in 245 nasal mucosa and zinc depleted-fibroblasts synthesized less collagen compared to 246 control cells. Considering that eosinophil infiltration and decreased collagen 247 expression in nasal mucosa are hallmarks of CRSwNP, it has been postulated that 248 depleted zinc levels might play a role in the formation of nasal polyps(12). Moreover, 249 since tissue eosinophilia is often seen in CRS patients in relation to severity of disease, 250 mucosal zinc levels and MT3 expression might also relate to disease severity and 251 outcomes after surgery in those patients(13, 14). More research into the potential 252 relationship between disease severity and mucosal zinc levels is needed to evaluate 253 this hypothesis.

254

255 So far, there have been no standard methods to examine mucosal zinc levels in 256 daily practice. Zinquin, the ultraviolet-excitable zinc-specific fluorophore, has been 257 used to visualize tissue zinc in airways, but only for research purposes. It requires 258 special equipment such as confocal laser microscopy and advanced imaging 259 techniques and is a semi-quantitative technique to evaluate labile zinc levels. 260 It has been well documented that MT3 expression is strictly regulated by 261 intracellular zinc levels through metal response elements (MRE) present in the 262 promoter region of metallothionein genes. Intracellular zinc activates MRE-binding 263 transcription factor-1 (MTF-1). The activated MTF-1 binds to MRE and promotes 264 MT3 expression (Figure 4)(31-33). In contrast, depletion of intracellular zinc levels 265 suppresses the activity of MTF-1, resulting in decreased MT3 expression. These

known mechanisms of transcriptional regulation of MT3 expression by intracellular
zinc levels support the potential for MT3 mRNA expression to be used as a biomarker
for tissue zinc levels in nasal mucosa. Interestingly, this theoretical framework of
MT3 gene regulation matches our findings of reduced MT3 mRNA and protein levels
in relation to reduced zinc levels in HNECs as well as results of our previous study
showing a reduced MT3 mRNA expression in CRSwNP patients in relation to
depleted tissue zinc levels(11).

273 From a clinical viewpoint, it could be more applicable to examine MT3 274 mRNA than MT3 or zinquin fluorescence intensity, as mRNA is more readily 275 examined with qPCR and does not require special equipment such as confocal laser 276 microscopy and advanced imaging techniques. Also, analysis of MT3 mRNA allows 277 for more precise quantitation as compared to semi-quantitative methods relying on 278 fluorescence. In general, immunofluorescence provides MT3 or zinquin intensity as 279 relative values to other samples put on the same slide. In this research, we constructed 280 the TMA slide containing 36 samples so that fluorescence intensity of the different 281 samples could be compared under the same condition. Whereas immunofluorescence 282 analysis using TMA slides therefore more accurately define relative protein/cellular 283 content, the use of such techniques is not applicable in clinical practice. In contrast, 284 intramucosal zinc levels could be more readily predicted by MT3 mRNA levels 285 allowing more accurate comparison among different samples measured at different 286 times and places.

287

It is unknown whether reduced MT3 expression plays a role in the pathophysiology of CRSwNP. MT3 has been shown to protect against airway inflammation induced by Ovalbumin(34), indicating a potential beneficial role for

- 291 MT3 in allergic airway disease. MT3 might have a protective role for airway
- inflammation in the nasal cavity as well. Further study will be necessary to unravel

the exact role of MT3 in the pathogenesis of CRS.

294

295

296 CONCLUSION

MT3 expression reflects intramucosal zinc levels in both nasal mucosa and HNECs indicating MT3 could be used as a clinical biomarker for monitoring intracellular zinc levels in the nasal mucosa.

300

302 ACKNOWLEDGEMENTS

303 We are grateful to Sophia Moraitis, Annette Kreutner, Yuka Masuta, Shizuka

304 Sugawara, Yumiko Kimura, and Ayaka Kubota for help in preparing the tissue

305 microarray and the manuscript.

306

307 AUTHORSHIP CONTRIBUTION

308 MS, YN, and SV designed the experiments. AJP, AH, and PJW supervised the

309 project. MS and MR performed most of the experiments and compiled the data. CC

and KO performed sample preparation. MS, MR, KO, and SV wrote the manuscript.

- 311 All authors provided feedback on the manuscript.
- 312

313 DISCLOSURE STATEMENT

314 None of the authors have any conflicts of interest or financial disclosures that

are relevant to this study.

318 REFERENCES

319 1. Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Alt JA, Baroody FM, et al. 320 International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int 321 Forum Allergy Rhinol. 2016;6 Suppl 1:S22-209. 322 2. Kato A. Immunopathology of chronic rhinosinusitis. Allergology 323 international : official journal of the Japanese Society of Allergology. 324 2015;64(2):121-30. 325 Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. 3. 326 European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinology 327 Supplement. 2012(23):3 p preceding table of contents, 1-298. 328 4. Tsai YL, Ko WS, Hsiao JL, Pan HH, Chiou YL. Zinc sulfate improved the 329 unbalanced T cell profiles in Der p-allergic asthma: An ex vivo study. The clinical 330 respiratory journal. 2018;12(2):563-71. 331 5. Lu H, Xin Y, Tang Y, Shao G. Zinc suppressed the airway inflammation in 332 asthmatic rats: effects of zinc on generation of eotaxin, MCP-1, IL-8, IL-4, and IFNgamma. Biological trace element research. 2012;150(1-3):314-21. 333 334 6. Beck FW, Prasad AS, Kaplan J, Fitzgerald JT, Brewer GJ. Changes in 335 cytokine production and T cell subpopulations in experimentally induced zinc-336 deficient humans. The American journal of physiology. 1997;272(6 Pt 1):E1002-7. 337 Truong-Tran AQ, Ruffin RE, Foster PS, Koskinen AM, Coyle P, Philcox JC, 7. 338 et al. Altered zinc homeostasis and caspase-3 activity in murine allergic airway 339 inflammation. American journal of respiratory cell and molecular biology. 340 2002;27(3):286-96. 341 8. Gray NA, Dhana A, Stein DJ, Khumalo NP. Zinc and atopic dermatitis: a 342 systematic review and meta-analysis. Journal of the European Academy of 343 Dermatology and Venereology : JEADV. 2019;33(6):1042-50. 344 Zalewski PD, Truong-Tran AQ, Grosser D, Jayaram L, Murgia C, Ruffin RE. 9. 345 Zinc metabolism in airway epithelium and airway inflammation: basic mechanisms and clinical targets. A review. Pharmacology & therapeutics. 2005;105(2):127-49. 346 347 Suzuki M, Suzuki T, Watanabe M, Hatakeyama S, Kimura S, Nakazono A, et 10. 348 al. Role of intracellular zinc in molecular and cellular function in allergic 349 inflammatory diseases. Allergology international : official journal of the Japanese 350 Society of Allergology. 2020(in press). 351 Murphy J, Ramezanpour M, Roscioli E, Psaltis AJ, Wormald PJ, Vreugde S. 11. 352 Mucosal zinc deficiency in chronic rhinosinusitis with nasal polyposis contributes to 353 barrier disruption and decreases ZO-1. Allergy. 2018;73(10):2095-7. 354 Suzuki M, Ramezanpour M, Cooksley C, Lee TJ, Jeong B, Kao S, et al. Zinc-12. 355 depletion associates with tissue eosinophilia and collagen depletion in chronic 356 rhinosinusitis. Rhinology. 2020. 357 Tokunaga T, Sakashita M, Haruna T, Asaka D, Takeno S, Ikeda H, et al. 13. 358 Novel scoring system and algorithm for classifying chronic rhinosinusitis: the 359 JESREC Study. Allergy. 2015;70(8):995-1003. 360 Fujieda S, Imoto Y, Kato Y, Ninomiya T, Tokunaga T, Tsutsumiuchi T, et al. 14. 361 Eosinophilic chronic rhinosinusitis. Allergology international : official journal of the 362 Japanese Society of Allergology. 2019;68(4):403-12. 363 Cooksley C, Roscioli E, Wormald PJ, Vreugde S. TLR response pathways in 15.

364 NuLi-1 cells and primary human nasal epithelial cells. Mol Immunol. 2015;68(2 Pt

365 B):476-83. 366 16. Ramezanpour M, Bolt H, Psaltis A, Wormald PJ, Vreugde S. Inducing a 367 Mucosal Barrier-Sparing Inflammatory Response in Laboratory-Grown Primary 368 Human Nasal Epithelial Cells. Current protocols in toxicology. 2019:e69. Suzuki M, Ramezanpour M, Cooksley C, Li J, Nakamaru Y, Homma A, et al. 369 17. 370 Sirtuin-1 Controls Poly (I:C)-Dependent Matrix Metalloproteinase 9 Activation in 371 Primary Human Nasal Epithelial Cells. American journal of respiratory cell and molecular biology. 2018;59(4):500-10. 372 373 Bassiouni A, Ou J, Rajiv S, Cantero D, Vreugde S, Wormald PJ. Subepithelial 18. 374 inflammatory load and basement membrane thickening in refractory chronic 375 rhinosinusitis with nasal polyposis: a histopathological study. Int Forum Allergy 376 Rhinol. 2016;6(3):248-55. 377 19. Ramezanpour M, Moraitis S, Smith JL, Wormald PJ, Vreugde S. Th17 378 Cytokines Disrupt the Airway Mucosal Barrier in Chronic Rhinosinusitis. Mediators 379 of inflammation. 2016;2016:9798206. 380 Oue S, Ramezanpour M, Paramasivan S, Miljkovic D, Cooksley CM, 20. 381 Bassiouni A, et al. Increased IL-13 expression is independently associated with neo-382 osteogenesis in patients with chronic rhinosinusitis. The Journal of allergy and clinical 383 immunology. 2017;140(5):1444-8.e11. 384 21. Kogan S, Sood A, Garnick MS. Zinc and Wound Healing: A Review of Zinc 385 Physiology and Clinical Applications. Wounds : a compendium of clinical research 386 and practice. 2017;29(4):102-6. Xin L, Yang X, Cai G, Fan D, Xia Q, Liu L, et al. Serum Levels of Copper 387 22. and Zinc in Patients with Rheumatoid Arthritis: a Meta-analysis. Biological trace 388 389 element research. 2015;168(1):1-10. 390 Canatan H, Bakan I, Akbulut M, Halifeoglu I, Cikim G, Baydas G, et al. 23. 391 Relationship among levels of leptin and zinc, copper, and zinc/copper ratio in plasma 392 of patients with essential hypertension and healthy normotensive subjects. Biological 393 trace element research. 2004;100(2):117-23. 394 Mezzaroba L, Alfieri DF, Colado Simao AN, Vissoci Reiche EM. The role of 24. 395 zinc, copper, manganese and iron in neurodegenerative diseases. Neurotoxicology. 396 2019;74:230-41. 397 25. Ohashi W, Fukada T. Contribution of Zinc and Zinc Transporters in the 398 Pathogenesis of Inflammatory Bowel Diseases. Journal of immunology research. 399 2019;2019:8396878. 400 26. Sanjeevi N, Freeland-Graves J, Beretvas SN, Sachdev PK. Trace element 401 status in type 2 diabetes: A meta-analysis. Journal of clinical and diagnostic research : 402 JCDR. 2018;12(5):Oe01-oe8. 403 Karahan SC, Deger O, Orem A, Ucar F, Erem C, Alver A, et al. The effects of 27. 404 impaired trace element status on polymorphonuclear leukocyte activation in the 405 development of vascular complications in type 2 diabetes mellitus. Clinical chemistry 406 and laboratory medicine. 2001;39(2):109-15. 407 Ariaee N, Farid R, Shabestari F, Shabestari M, Jabbari Azad F. Trace 28. 408 Elements Status in Sera of Patients with Allergic Asthma. Reports of biochemistry & 409 molecular biology. 2016;5(1):20-5. 410 29. Guo CH, Liu PJ, Hsia S, Chuang CJ, Chen PC. Role of certain trace minerals 411 in oxidative stress, inflammation, CD4/CD8 lymphocyte ratios and lung function in 412 asthmatic patients. Annals of clinical biochemistry. 2011;48(Pt 4):344-51. 413 Unal M, Tamer L, Pata YS, Kilic S, Degirmenci U, Akbas Y, et al. Serum 30. 414 levels of antioxidant vitamins, copper, zinc and magnesium in children with chronic

- 415 rhinosinusitis. Journal of trace elements in medicine and biology : organ of the
- 416 Society for Minerals and Trace Elements (GMS). 2004;18(2):189-92.
- 417 31. Otsuka F, Okugaito I, Ohsawa M, Iwamatsu A, Suzuki K, Koizumi S. Novel
- 418 responses of ZRF, a variant of human MTF-1, to in vivo treatment with heavy metals. 410 Riochimica at hisphysica acta 2000;1402(2,3);220,40
- 419 Biochimica et biophysica acta. 2000;1492(2-3):330-40.
- 420 32. Saydam N, Adams TK, Steiner F, Schaffner W, Freedman JH. Regulation of
- 421 metallothionein transcription by the metal-responsive transcription factor MTF-1:
- 422 identification of signal transduction cascades that control metal-inducible
- 423 transcription. The Journal of biological chemistry. 2002;277(23):20438-45.
- 424 33. Naruse S, Igarashi S, Furuya T, Kobayashi H, Miyatake T, Tsuji S. Structures
- 425 of the human and mouse growth inhibitory factor-encoding genes. Gene.
- 426 1994;144(2):283-7.
- 427 34. Inoue K, Takano H, Yanagisawa R, Sakurai M, Ichinose T, Sadakane K, et al.
- 428 Role of metallothionein in antigen-related airway inflammation. Experimental biology
- 429 and medicine (Maywood, NJ). 2005;230(1):75-81.
- 430

431 FIGURE LEGENDS

432 Figure 1. MT3 expression is decreased in the surface epithelium and lamina

433 propria in CRSwNP.

434 A. Immunofluorescence of representative control, CRSsNP and CRSwNP patients

435 using Zinquin (blue staining) and MT3 antibody (red staining). B and C. MT3

436 fluorescence intensity between the different patient groups was compared in the

437 surface epithelium (B) and the lamina propria (C) in nasal mucosa. *p<0.05,

438 Wilcoxon test.

439

440 Figure 2. MT3 expression positively correlated with zinc levels in nasal mucosa.

441 Pearson's correlation coefficient between MT3 and Zinquin fluorescence in the lamina

442 propria of nasal mucosa is shown in a scatter diagram with 99% (red), 95% (green),

443 90% (blue), and 50% (purple) probability eclipses, respectively. Skyblue, orange, and

444 gray points stand for CRSwNP, CRSsNP and control, respectively.

445

446 Figure 3. MT3 expression correlates with zinc levels in nasal epithelial cells.

447 A-D. HNECs were incubated for 48 hours in zinc depleted (ZD) or control media

followed by immunofluorescence using MT3 antibodies (A, B, and D) and by qPCR

449 using MT3 primers (C). Data are means ± standard deviation (s.d.) of values from at

450 least three independent experiments. P values for indicated comparisons were

451 determined by t-test. *p<0.05. D. Zinquin and MT3 fluorescence intensity per HNEC

- 452 was shown in a scatter diagram. The correlations between the zinquin and MT3
- 453 fluorescence intensity were tested using Pearson's correlation coefficient.

454

455 Figure 4. MT3 expression correlates with intracellular zinc levels.

- 456 Free intracellular zinc activates metal response elements (MRE)-binding transcription
- 457 factor-1 (MTF-1). MT3 expression is regulated by binding of activated MTF-1 to
- 458 MRE located in the promotor region of MT-3 promoting MT3 mRNA expression (31-
- 459 33). Depleted intracellular zinc fails to activate MTF-1 resulting in decreased MT3460 expression.
- 461

462 Supplementary Figure 1. MT3 expression correlates with intracellular zinc levels.

- 463 For each specimen, at least 3 areas of the epithelium and the lamina propria were
- 464 randomly selected as a region of interest (ROI), then quantification of zinquin and
- 465 MT-3 fluorescence intensity was performed at the area.
- 466

M Suzuki, MT3 figure 1



M Suzuki, MT3 figure 2



M Suzuki, MT3 figure 3



M Suzuki, MT3 figure 4

